share_log

CORRESP: CORRESP

SEC ·  Sep 10, 2024 10:33

Summary by Moomoo AI

ZyVersa Therapeutics, Inc. has officially requested the U.S. Securities and Exchange Commission (SEC) to declare its Registration Statement on Form S-3 effective as of September 9, 2024, at 5:00 p.m. Eastern Time. The request, made under Rule 461 of the Securities Act of 1933, as amended, was submitted through a correspondence filed via EDGAR. The company, based in Weston, Florida, has indicated that the effective date and time are subject to change if they notify the SEC otherwise. ZyVersa's CEO, Stephen C. Glover, signed the request, and the company's outside counsel, Faith L. Charles of Thompson Hine LLP, is the point of contact for any inquiries related to this matter.
ZyVersa Therapeutics, Inc. has officially requested the U.S. Securities and Exchange Commission (SEC) to declare its Registration Statement on Form S-3 effective as of September 9, 2024, at 5:00 p.m. Eastern Time. The request, made under Rule 461 of the Securities Act of 1933, as amended, was submitted through a correspondence filed via EDGAR. The company, based in Weston, Florida, has indicated that the effective date and time are subject to change if they notify the SEC otherwise. ZyVersa's CEO, Stephen C. Glover, signed the request, and the company's outside counsel, Faith L. Charles of Thompson Hine LLP, is the point of contact for any inquiries related to this matter.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Heat List
    US
    SymbolLatest Price% Chg

    No Data

    Hot News
    Updated